File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Outcomes of pediatric chronic myeloid leukemia diagnosed in chronic phase in Hong Kong

TitleOutcomes of pediatric chronic myeloid leukemia diagnosed in chronic phase in Hong Kong
Authors
KeywordsMedical sciences
Oncology medical sciences
Pediatrics
Issue Date2013
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1545-5017/
Citation
The 45th Congress of the International Society of Paediatric Oncology (SIOP 2013), Hong Kong, China, 25-28 September 2013. In Pediatric Blood & Cancer, 2013, v. 60 S3, p. 72, abstract no. P-0074 How to Cite?
AbstractPURPOSE/OBJECTIVE: To determine the outcomes in children with chronic myeloid leukemia (CML) diagnosed in chronic phase (CP) in Hong Kong. Materials and METHODS: We retrospectively reviewed the clinical data of children with CML diagnosed in CP treated in all 5 pediatric oncology units in Hong Kong from 1996 to 2011. RESULTS: Thirty-one children were diagnosed with CML in CP (median age 12.7 years, range 5.6-17.9 years, 24 were males). Treatments included imatinib (n = 1), hydroxyurea followed by imatinib (n = 18), hydroxyurea and cytarabine followed by imatinib (n = 4), hydroxyurea and interferon followed by imatinib (n ? 1), hydroxyurea alone (n = 5), or hydroxyurea followed by interferon (n = 2). Five patients proceeded to allogeneic hematopoietic stem cell transplant (HSCT) (matched sibling donor: n = 4, matched unrelated donor: n = 1). All 24 patients on imatinib achieved complete hematological response at a median of 5.2 weeks (range, 0.7-20.1 weeks), 16 patients achieved complete cytogenetic response at a median of 10.9 months (range, 3.2-44.6 months), and 16 patients achieved major molecular response at a median of 20.1 months (range, 6.7-48.3 months). Seven patients progressed to blastic phase at a median of 8.6 months after diagnosis (range, 0.8-76.9 months), 4 of whom had not received imatinib. Five-year overall survival (OS) and progression-free survival (PFS) were 89.5% and 80.1% for all patients, and were better for patients treated with imatinib compared to those who were not (OS: 95.5% vs. 66.7%, p ? 0.024; PFS: 91.7% vs. 34.3%, p < 0.001). Patients who remained on imatinib also appeared to have better survivals compared to those who proceeded to HSCT (OS: 95.0% vs. 80.0%; PFS: 90.9% vs. 80.0%), though the differences were not statistically significant. CONCLUSIONS: Outcome of pediatric CML diagnosed in chronic phase is favorable, especially for those who were treated with imatinib. Imatinib or other tyrosine kinase inhibitors could be a durable form of first-line treatment and the role of HSCT may have to be reevaluated in future study.
DescriptionThis journal suppl. entitled: Supplement: SIOP Abstratcs: 45th Congress of the International Society of Paediatric Oncology (SIOP) ... 2013
Poster Session - Myeloid Leukemias: abstract no. P-0074
Persistent Identifierhttp://hdl.handle.net/10722/197709
ISSN
2015 Impact Factor: 2.634
2015 SCImago Journal Rankings: 1.505

 

DC FieldValueLanguage
dc.contributor.authorCheuk, DKLen_US
dc.contributor.authorLeung, AWKen_US
dc.contributor.authorLuk, CWen_US
dc.contributor.authorLi, CHen_US
dc.contributor.authorLing, SCen_US
dc.contributor.authorLee, Ven_US
dc.contributor.authorHa, SYen_US
dc.contributor.authorYuen, HLen_US
dc.contributor.authorShing, MMKen_US
dc.contributor.authorChan, Gen_US
dc.date.accessioned2014-05-29T08:45:05Z-
dc.date.available2014-05-29T08:45:05Z-
dc.date.issued2013en_US
dc.identifier.citationThe 45th Congress of the International Society of Paediatric Oncology (SIOP 2013), Hong Kong, China, 25-28 September 2013. In Pediatric Blood & Cancer, 2013, v. 60 S3, p. 72, abstract no. P-0074en_US
dc.identifier.issn1545-5009-
dc.identifier.urihttp://hdl.handle.net/10722/197709-
dc.descriptionThis journal suppl. entitled: Supplement: SIOP Abstratcs: 45th Congress of the International Society of Paediatric Oncology (SIOP) ... 2013-
dc.descriptionPoster Session - Myeloid Leukemias: abstract no. P-0074-
dc.description.abstractPURPOSE/OBJECTIVE: To determine the outcomes in children with chronic myeloid leukemia (CML) diagnosed in chronic phase (CP) in Hong Kong. Materials and METHODS: We retrospectively reviewed the clinical data of children with CML diagnosed in CP treated in all 5 pediatric oncology units in Hong Kong from 1996 to 2011. RESULTS: Thirty-one children were diagnosed with CML in CP (median age 12.7 years, range 5.6-17.9 years, 24 were males). Treatments included imatinib (n = 1), hydroxyurea followed by imatinib (n = 18), hydroxyurea and cytarabine followed by imatinib (n = 4), hydroxyurea and interferon followed by imatinib (n ? 1), hydroxyurea alone (n = 5), or hydroxyurea followed by interferon (n = 2). Five patients proceeded to allogeneic hematopoietic stem cell transplant (HSCT) (matched sibling donor: n = 4, matched unrelated donor: n = 1). All 24 patients on imatinib achieved complete hematological response at a median of 5.2 weeks (range, 0.7-20.1 weeks), 16 patients achieved complete cytogenetic response at a median of 10.9 months (range, 3.2-44.6 months), and 16 patients achieved major molecular response at a median of 20.1 months (range, 6.7-48.3 months). Seven patients progressed to blastic phase at a median of 8.6 months after diagnosis (range, 0.8-76.9 months), 4 of whom had not received imatinib. Five-year overall survival (OS) and progression-free survival (PFS) were 89.5% and 80.1% for all patients, and were better for patients treated with imatinib compared to those who were not (OS: 95.5% vs. 66.7%, p ? 0.024; PFS: 91.7% vs. 34.3%, p < 0.001). Patients who remained on imatinib also appeared to have better survivals compared to those who proceeded to HSCT (OS: 95.0% vs. 80.0%; PFS: 90.9% vs. 80.0%), though the differences were not statistically significant. CONCLUSIONS: Outcome of pediatric CML diagnosed in chronic phase is favorable, especially for those who were treated with imatinib. Imatinib or other tyrosine kinase inhibitors could be a durable form of first-line treatment and the role of HSCT may have to be reevaluated in future study.-
dc.languageengen_US
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1545-5017/-
dc.relation.ispartofPediatric Blood & Canceren_US
dc.rightsPediatric Blood & Cancer. Copyright © John Wiley & Sons, Inc.-
dc.subjectMedical sciences-
dc.subjectOncology medical sciences-
dc.subjectPediatrics-
dc.titleOutcomes of pediatric chronic myeloid leukemia diagnosed in chronic phase in Hong Kongen_US
dc.typeConference_Paperen_US
dc.identifier.emailCheuk, DKL: klcheuk@hkucc.hku.hken_US
dc.identifier.emailHa, SY: syha@hku.hken_US
dc.identifier.emailChan, G: gcfchan@hku.hken_US
dc.identifier.authorityChan, G=rp00431en_US
dc.identifier.doi10.1002/pbc.24719-
dc.identifier.hkuros229018en_US
dc.identifier.volume60-
dc.identifier.issueS3-
dc.identifier.spage72-
dc.identifier.epage72-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats